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Metabolic reprogramming induced by ketone
bodies diminishes pancreatic cancer cachexia
Surendra K Shukla1, Teklab Gebregiworgis2, Vinee Purohit1,3, Nina V Chaika1, Venugopal Gunda1,
Prakash Radhakrishnan1, Kamiya Mehla1, Iraklis I Pipinos4,5, Robert Powers2, Fang Yu6 and Pankaj K Singh1,3,7,8*
Abstract
Background: Aberrant energy metabolism is a hallmark of cancer. To fulfill the increased energy requirements, tumor
cells secrete cytokines/factors inducing muscle and fat degradation in cancer patients, a condition known as cancer
cachexia. It accounts for nearly 20% of all cancer-related deaths. However, the mechanistic basis of cancer cachexia and
therapies targeting cancer cachexia thus far remain elusive. A ketogenic diet, a high-fat and low-carbohydrate diet that
elevates circulating levels of ketone bodies (i.e., acetoacetate, β-hydroxybutyrate, and acetone), serves as an alternative
energy source. It has also been proposed that a ketogenic diet leads to systemic metabolic changes. Keeping in view
the significant role of metabolic alterations in cancer, we hypothesized that a ketogenic diet may diminish glycolytic
flux in tumor cells to alleviate cachexia syndrome and, hence, may provide an efficient therapeutic strategy.
Results: We observed reduced glycolytic flux in tumor cells upon treatment with ketone bodies. Ketone bodies also
diminished glutamine uptake, overall ATP content, and survival in multiple pancreatic cancer cell lines, while inducing
apoptosis. A decrease in levels of c-Myc, a metabolic master regulator, and its recruitment on glycolytic gene promoters,
was in part responsible for the metabolic phenotype in tumor cells. Ketone body-induced intracellular metabolomic
reprogramming in pancreatic cancer cells also leads to a significantly diminished cachexia in cell line models. Our mouse
orthotopic xenograft models further confirmed the effect of a ketogenic diet in diminishing tumor growth and cachexia.
Conclusions: Thus, our studies demonstrate that the cachectic phenotype is in part due to metabolic alterations in
tumor cells, which can be reverted by a ketogenic diet, causing reduced tumor growth and inhibition of muscle and
body weight loss.
Keywords: Pancreatic cancer, Cancer cachexia, Cancer metabolism, Ketone bodies
Background
Pancreatic cancer is the fourth leading cause of cancer-
related deaths in the USA [1]. Pancreatic ductal adeno-
carcinoma (PDAC) accounts for 95% of all pancreatic
cancer cases [2]. Despite advances in the understanding
of pancreatic cancer biology, effective chemotherapeutic
modalities for the treatment of patients remain to be de-
veloped. In addition to the aggressive pathogenesis,
around 83% of pancreatic cancer patients demonstrate
cancer-induced cachexia, which significantly contributes
to cancer-related deaths [3]. Thus, inhibition of cachexia
along with cancer cell growth may be an effective strat-
egy for the management of pancreatic cancer.
Cachexia, a metabolic syndrome, leads to a loss of
muscle weight and the depletion of fat deposits. Al-
though an association of cachexia with various types of
cancers has been known for a long time, the molecular
mechanism of cancer-induced cachexia is poorly under-
stood [4]. Cachexia is triggered by a large number of
tumor and host-derived catabolic factors and pro-
inflammatory cytokines such as IL-6, TNFα, and IFN-γ,
which lead to changes in host metabolism and energy
expenditure [4]. It has been proposed that excessive con-
sumption of glucose by a growing tumor first leads to a
depletion of glucose in the blood. At later stages of
tumor growth, a depletion of glycogen stores in the liver
occurs. Glycogen depletion is followed by muscle deg-
radation and depletion of adipose deposits. All these
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account for the cachexia syndrome and result in a poor
response to chemotherapy, fatigue, and a reduced quality
of life for cancer patients [5].
Cancer cells exhibit reprogramming of several metabolic
pathways along with multiple genetic, epigenetic, and
growth signaling alterations [6,7]. Most cancer cells dem-
onstrate an increase in glucose uptake, a higher rate of
glycolysis, and an increase in lactate secretion despite the
presence of oxygen, a phenomenon known as the War-
burg effect [8]. Aerobic glycolysis plays an important role
in rapid cellular growth as it provides several intermedi-
ates required for biomass synthesis by routing the carbon
flux through the pentose phosphate pathway [9]. The in-
creased conversion of pyruvate into lactate by aerobic gly-
colysis leads to acidosis in tumor microenvironments that
facilitates invasion and metastasis of cancer cells [10]. Aer-
obic glycolysis is also an energy-inefficient process requir-
ing large amounts of glucose. Correspondingly, tumor
cells serve as a glucose sink [11]. Additionally, lactate pro-
duced from tumor cells passes to the liver and gets con-
verted to glucose by means of the Cori cycle, another
energy-inefficient process [9]. Along with glucose uptake
and enhanced aerobic glycolysis, cancer patients also
present glucose intolerance and increased hepatic glucose
production [12]. An increased requirement for glucose
might be the critical stimulus needed for enhanced hepatic
glucose production. Tumor cells also have alterations in
the metabolism of glutamine, a nitrogen source and argu-
ably the most significant metabolite precursor for tumor
cells after glucose [13].
A ketogenic diet is a high-fat and low-carbohydrate
diet that leads to elevated circulating levels of ketone
bodies (i.e., acetoacetate, β-hydroxybutyrate, and acet-
one) and an alternative energy source [14]. Ketogenic
diets possess anticonvulsant and antiinflammatory ac-
tivities [15,16]. It has also been proposed that a keto-
genic diet treatment results in systemic metabolic
changes like increased glucose tolerance, reduced fatty
acid synthesis, and weight loss [17]. Keeping in view the
significant role of inflammation and metabolic alter-
ations in cancer, a ketogenic diet may provide an effi-
cient therapeutic strategy. Furthermore, most cancer
cells lack key mitochondrial enzymes to metabolize ke-
tone bodies and generate ATP, while myocytes and
other tissues, including the brain, still retain this ability
[18]. Hence, a ketogenic diet may act against the
cancer-induced cachexia while causing minimal side ef-
fects as previously it has been shown that a 2–7-mM ke-
tone body concentration can be achieved safely without
giving rise to clinical acidosis [19,20]. In the present
study, we have evaluated anticancerous and anticachec-
tic properties of ketone bodies in cell culture conditions,
as well as the effect of a ketogenic diet on tumor burden
and cachexia in animal models. Furthermore, our
studies establish a ketone body-induced metabolomic
reprogramming as the mechanism of action of a keto-
genic diet against cancer and cancer-induced cachexia.
Methods
Cells and reagents
The human pancreatic cancer cell line Capan1, mouse
myoblast C2C12, and mouse embryo fibroblast (preadi-
pocyte) 3T3L1 were obtained from American Type Cul-
ture Collection (Manassas, VA, USA). S2-013 is a cloned
subline of a human pancreatic tumor cell line (SUIT-2)
derived from a liver metastasis [21]. All the cell lines
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum,
penicillin (100 mg/mL), and streptomycin (100 mg/mL)
and incubated at 37°C in a humidified chamber with 5%
CO2. Sodium-3-hydroxybutyrate, lithium acetoacetate,
dihydroethidium (DHE), 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT), BCPCF, and S-
hydroxy butyric acid were purchased from Sigma Che-
micals (Sigma-Aldrich, St. Louis, MO, USA).
Cell viability and caspase 3/7 activity assay
Cell viability was determined by performing MTT assay.
Capan1 and S2-013 cells (5 × 103 cells per well) were
seeded in 96-well plates for 12 h and then treated with
different concentrations of sodium-3-hydroxybutyrate or
lithium acetoacetate for 72 h. After treatment, cells were
incubated with MTT reagent for 2 h; the resultant for-
mazan crystals were dissolved in dimethyl sulfoxide and
the absorbance was recorded at 590 nm. Untreated cells
were utilized as a control for the viability assays. Caspase
3/7 activity was determined by utilizing a Promega
Caspase-Glo kit (Madison, WI, USA). Capan1 and S2-
013 cells (0.6 × 106 cells per well) were seeded in 6-well
plates for 12 h and then treated with different concen-
trations of sodium-3-hydroxybutyrate and lithium acet-
oacetate for 48 h. Caspase 3/7 activity was then
determined as per the manufacturer’s protocol.
Glucose and glutamine uptake assay
To determine glucose uptake, Capan1 and S2-013 cells
(5 × 104 cells per well) were seeded in 24-well plates. After
12 h, cells were treated with multiple concentrations of
sodium-3-hydroxybutyrate and lithium acetoacetate for
24 h. After treatment, cells were starved for glucose for
2 h and then incubated for 20 min with 1 μCi [3H]-2-
deoxyglucose (DG) for a glucose uptake assay. Cells were
washed with phosphate-buffered saline (PBS) and lysed
with 1% sodium dodecyl sulfate (SDS). The lysates were
then subjected to [3H] counting by utilizing a scintillation
counter. Scintillation counts from cells treated with
labeled and excess unlabeled 2-DG were utilized as con-
trols for baseline correction. The results were normalized
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to the cell counts. For determining glutamine uptake,
Capan1 and S2-013 cells (5 × 104 cells per well) were
seeded in 24-well plates. After 12 h, cells were treated with
solvent control, multiple concentrations of sodium-3-
hydroxybutyrate, or lithium acetoacetate for 24 h. Post
treatment, cells were starved for glutamine for 2 h and then
incubated for 3 min with 1 μCi tritiated Glutamine, L-[3,4-
3H(N)]. Cells were washed with PBS and lysed in 1% SDS.
The lysates were used for [3H] counting by utilizing a scin-
tillation counter. Scintillation counts from cells treated with
labeled and excess unlabeled glutamine were utilized as
controls for baseline correction. The results were normal-
ized to the cell counts.
Lactate release assay
Capan1 and S2-013 cells (5 × 104 cells per well) were
seeded in 24-well plates. After 12 h, cells were treated with
indicated concentrations of sodium-3-hydroxybutyrate or
lithium acetoacetate for 24 h. The culture supernatants
were then utilized for determining lactate release. The
assay was performed by utilizing a Lactate Assay Kit (Eton
Bioscience Inc., San Diego, CA, USA), as per the manufac-
turer’s protocol.
ATP assay
Total ATP level in cells was determined by using an ATP
assay kit (Roche, Indianapolis, IN, USA). After 12 h, cells
were treated with different concentrations of sodium-3-
hydroxybutyrate and lithium acetoacetate for 24 h and
ATP level was determined as per the manufacturer’s
protocol. ATP level was normalized with total protein
concentration.
Reactive oxygen species assay
Reactive oxygen species level was determined by using
oxidation-sensitive fluorescent dye DHE. Capan1 and S2-
013 cells (0.1 × 106 cells per well) were seeded in 12-well
plates on glass coverslips. After 12 h, cells were treated
with solvent control or indicated doses of sodium-3-
hydroxybutyrate and lithium acetoacetate for 24 h.
Control and treated cells were incubated at 37°C in
2.5 mM DHE containing DMEM. After incubation, cells
were washed with cold PBS and fixed with HistoChoice®
fixative (Sigma-Aldrich) for 15 min at room temperature.
Cells were washed with PBS and the coverslips were
mounted onto glass slides using real-mount. Fluorescence
intensity per cell was determined by scanning with Zeiss
Axiovert 200 M microscope (Oberkochen, Germany) and
analyzing the images with SlideBook 5.5 software (Intelli-
gent Imaging Innovations, Inc., Denver, CO, USA).
Gene expression analysis by qRT-PCR
Total RNA was isolated by utilizing RNeasy columns
(Qiagen, Venlo, The Netherlands) as per the manufacturer’s
protocol. Total RNA (5 μg) was reverse transcribed by
utilizing Verso-cDNA synthesis kit (Thermo Scientific,
Pittsburgh, PA, USA) according to the manufacturer’s
guidelines. Quantitative reverse transcription polymer-
ase chain reaction (qRT-PCR) was performed with
gene-specific primers at 95°C for 10 s and 60°C for 60 s
(40 cycles) in 10 μL reaction mix containing 3 μL
cDNA, 2 μL primers, and 5 μL SYBR Green Master Mix
(Applied Biosystems, Grand Island, NY, USA) using an
ABI 7500 thermocycler. Beta-actin was utilized as an in-
ternal control. The sequence of different sets of primers
used in the study is given in Additional file 1. Quantifi-
cation was performed with the ΔΔCt method [22].
Immunoblotting
For immunoblotting, cells were washed twice with cold
PBS and lysed in RIPA lysis buffer by incubating at 4°C
rotatory shaker for 30 min. Cell debris was removed by
centrifugation at 13,000 rpm for 10 min and the super-
natant was collected. Protein content was measured by
performing Bradford assay. Western blotting was per-
formed as described previously [23]. The membranes
were probed with primary antibody against GLUT1
(Abcam, Cambridge, UK), c-Myc-9E10 (Santa Cruz Bio-
technology, Dallas, TX, USA), HKII (Cell Signaling
Technology, Beverly, MA, USA), and HSP90 (Santa Cruz
Biotechnology).
Luciferase assay
c-Myc-promoter (del1)-luciferase reporter construct was
obtained from Addgene (Cambridge, MA, USA) [24].
Cells were transfected with 1 μg of plasmid, and 16 h
post transfection, cells were treated with different ketone
bodies for 24 h. A synthetic Renilla luciferase reporter
pRL-TK was utilized as a transfection control. Luciferase
activity was determined by utilizing Dual-Luciferase Re-
porter Assay System (Promega).
Chromatin immunoprecipitation
For chromatin immunoprecipitation, cells were treated
with 20 mM sodium-3-hydroxybutyrate and lithium
acetoacetate for 24 h along with solvent control. Chro-
matin immunoprecipitation was performed by utilizing
c-Myc antibody (9E10) as described previously [25].
Mouse IgG was utilized as a control. qPCR data were
normalized to a genomic region located within GUSB
gene and represented as fold enrichment relative to the
IgG control. Primer sequences used for qPCR amplifica-
tion are described in Additional file 1.
Tumor growth measurement
Congenitally athymic female nude mice (NCr-nu/nu) were
purchased from the National Cancer Institute. Mice were
treated as per the guidelines of our institutional animal care
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and use committee (IACUC). S2-013 cells (5 × 105) were
used for orthotopic injections into the pancreas of nude
mice. After 7 days of implantation, mice were divided in
groups of nine animals each and fed ad libitum with a nor-
mal diet or a ketogenic diet (composition given in Table S2
in Additional file 1). After 3 weeks of treatment, mice were
sacrificed and tumor weight, tumor volume, muscle weight,
carcass weight, etc. were recorded. Tumor tissue and other
organs were flash frozen in liquid nitrogen for further ana-
lysis. Animal protocols were in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and
were approved by the University of Nebraska Medical Cen-
ter Animal Care and Use Committee.
Immunohistochemistry
Immunohistochemistry was performed as described previ-
ously [26]. Ki67 (Thermo Fisher Scientific, Waltham, MA,
USA), c-Myc (Epitomics, Burlingame, CA, USA), and
Cleaved Caspase 3 (Cell Signaling Technology) primary
antibodies were utilized. The stained sections were imaged
at × 20 under an upright microscope and representative im-
ages were captured and presented.
Metabolite extraction and NMR sample preparation
After confirming the confluence of the cells, the media
was aspirated and the cells were washed twice with 1×
phosphate buffer to remove remnants of the media before
lysing the cells. The cells were then cold shocked with
1 mL of cryogenically cold 80% methanol/water mixture.
The plates with the 80% methanol/water were incubated
in a −80°C freezer for at least 15 min. The cells from the
cold plates were scraped with a cell scraper and pipetted
into an Eppendorf tube and centrifuged at 13,000 rpm for
5 min. The supernatant was collected and 250 μL of Milli-
Q water (Millipore, Billerica, MA, USA) was added to the
remaining cell debris for re-extraction. After mixing the
cell debris with the water by pipetting, the sample was
again centrifuged at 13,000 rpm for 5 min. The new super-
natant was combined with the previously collected super-
natant. Finally, the sample was dried using speed vacuum
evaporator (SpeedVac® Plus, Savant, Thermo Scientific,
Waltham, MA) to evaporate the methanol and subjected
to freeze drying (Labconco, Kansas City, MO) to lyophilize
the water consecutively. The dried sample was made ready
for an NMR experiment by dissolving in 600 μL of 50 mM
phosphate buffer in 99.8% D2O (Isotec, St. Louis, MO) at
pH 7.2 (uncorrected) with 50 μM 3-(tetramethysilane)
propionic acid-2,2,3,3-d4 (TMSP) (500 μM for 2D
1H-13C
HSQC) for spectral referencing.
NMR experiment and data analysis
The NMR spectra were acquired on a Bruker AVANCE
DRX 500 MHz spectrometer equipped with 5 mm triple-
resonance cryogenic probe (1H, 13C, and 15 N) with a Z-
axis gradient. The NMR data collection was automated
using a BACS-120 sample changer, ATM (automatic tun-
ing and matching), and Bruker IconNMR™ software. The
one-dimensional (1D) proton nuclear magnetic resonance
(1H NMR) data was acquired using an excitation sculpting
pulse sequence to remove the solvent peak and maintain a
flat baseline [27]. The spectra were collected at 300 K with
32 K data points, 128 scans, 16 dummy scans, and a spec-
tral width of 5,483 Hz. Our MVAPACK software (http://
bionmr.unl.edu/mvapack.php) [28] was used to process
the 1D 1H NMR spectra. The raw NMR data was only
Fourier transformed and automatically phased. The result-
ing NMR spectrum was binned using an adaptive intelli-
gent binning algorithm that automatically adjusts bin sizes
to avoid splitting NMR resonances between multiple bins
[29]. The spectral region before the TMSP was used as a
training set to remove the noise from the data using the
method stated by Halouska et al. [30]. The spectra were
then normalized using standard normal variate (SNV) and
scaled using Pareto scaling. The processed data was uti-
lized to generate plots of principal component analysis
(PCA) and orthogonal projections to latent structures
discriminant analysis (OPLS-DA) scores and backscaled
loadings (Additional file 2) using our MVAPACK soft-
ware [28]. Metabolite identification from the 1D 1H
NMR spectra was accomplished using the Chenomx
NMR Suite 7.6 (http://www.chenomx.com/) and the
backscaled loadings.
The 2D 1H-13C hetero-nuclear single quantum coher-
ence (HSQC) NMR spectra were collected at 300 K with
64 scans, 16 dummy scans, and a 1.5-s relaxation delay.
The spectra were collected with 2 K data points and a
spectrum width of 4,735 Hz in the direct dimension and
64 data points and a spectrum width of 17,607 Hz in the
indirect dimension. The 2D 1H-13C HSQC NMR spectra
were processed using NMRPipe (NIH, Bethesda, Mary-
land) [31] and analyzed using NMRViewJ Version 8.0.3.
Peak intensities were normalized by the average peak in-
tensity for a given spectrum and then assigned to a me-
tabolite using chemical shift references from the Human
Metabolomics Database [32], Madison Metabolomics
Consortium Database [33], and Platform for RIKEN
Metabolomics [34]. Chemical shift errors of 0.08 and
0.25 ppm for the 1H and 13C chemical shifts, respect-
ively, were used to match the experimental chemical
shifts with the databases. In addition to chemical shifts,
peak splitting patterns and peak shapes were also used
to verify metabolite assignments.
The 2D 1H-13C HSQC NMR experiment is a more reli-
able approach for metabolite identification because of the
significantly higher signal dispersion, and the correlation
between 1H and 13C chemical shifts for each C-H pair in a
molecule [35]. More importantly, the 2D 1H-13C HSQC
experiment simplifies the analysis of the metabolome
Shukla et al. Cancer & Metabolism 2014, 2:18 Page 4 of 19
http://www.cancerandmetabolism.com/content/2/1/18
because only compounds containing a 13C-carbon derived
from the 13C6-glucose added to the media will be detected.
Thus, using 13C6-glucose will highlight metabolite changes
associated with the glycolytic flux in tumor cells. This
avoids the challenge with the 1D 1H NMR experiments
where the spectra were dominated by catabolic products
of ketone bodies. Thus, the identification of metabolites
from the 2D 1H-13C HSQC experiments is more reliable
and pertinent to the analysis of metabolic changes result-
ing from ketone body effects on pancreatic cancer
cachexia.
Each metabolite peak from the two sets (control and
ketone body-treated) of triplicate 2D 1H-13C HSQC NMR
spectra were further normalized by using the maximum
peak intensity for the metabolite and then scaled from 0
to 100. The peak intensities for each metabolite were
then averaged and compared between the control and
treated groups using a Student’s t test. Metabolites with
a p value <0.1 were used to generate a heat map using
the R statistical package [36]. A relative change in peak
intensity implies a corresponding metabolite concentra-
tion change. Absolute concentrations are not measur-
able from the 2D 1H-13C HSQC because other factors,
such as coupling constants, relaxation, and dynamics,
also contribute to peak intensities.
Measurement of blood glucose and β-hydroxybutyrate
concentration
Blood glucose level of mice was measured after 16 h of
starvation by utilizing Contour USB blood glucose meter
(Bayer Health Care, Mishawaka, Japan), as per the manu-
facturer’s protocol. Blood ketone level was measured by
utilizing a blood glucose and ketone monitor (Nova
Biomedical, Waltham, MA, USA) as per the manufac-
turer’s protocol. The concentration of β-hydroxybutyrate
was measured by comparing the TMSP-normalized me-
thyl peaks of 1H NMR collected for six animals.
C2C12 and 3T3L1 differentiation and conditioned
medium preparation
C2C12 mouse myoblasts were grown in DMEM with 10%
FBS. To induce differentiation, cells were switched to 2%
horse serum and 10 μg/mL insulin-containing DMEM
and grown for 72 h. 3T3L1 mouse embryo fibroblasts
were cultured in DMEM with 10% FBS. For differentiation
of 3T3L1 preadipocytes, after 2 days at confluency, cells
were treated with differentiation medium: DMEM con-
taining 10% FBS, 1 μM dexamethasone, 0.5 mM methyli-
sobutylxanthine (IBMX), and 1 μg/mL insulin for 2 days.
After 2 days, differentiation medium was replaced with
DMEM containing 10% FBS. Medium was changed regu-
larly after 48 h. For conditioned medium preparation, cells
were plated at a density of 50,000 cells/cm2, and after 12 h
of seeding, cells were washed twice with PBS and cultured
in serum-free DMEM for the next 24 h. Conditioned
medium was centrifuged at 1,200 g for 10 min and filtered
with a 0.2-μm syringe filter and used immediately or stored
at −80°C.
Measurement of intracellular pH
Cytosolic pH was measured by using fluorescence spec-
troscopy using BCPCF-AM as described by Marino
et al. [37].
Statistical analysis
Comparisons between different groups were performed by
using ANOVA (one-way; GraphPad Prism version 4.03)
with Dunnett’s post hoc test. Student’s t test was used for
in vivo studies. A p value of <0.05 was considered to be
significant.
Results
Ketone bodies diminish pancreatic cancer cell growth
and induce apoptosis in a dose-dependent manner
We investigated the effect of ketone bodies (sodium hydro-
xybutyrate and lithium acetoacetate) on cell survival in
multiple pancreatic cancer cell lines. Initially, we evaluated
the effect of multiple doses of sodium hydroxybutyrate and
lithium acetoacetate (1 to 20 mM) on the survival of
Capan1 and S2-013 pancreatic cancer cells by performing
MTT assays. Ketone bodies were observed to inhibit cell
survival in a dose-dependent manner. Ketone bodies signifi-
cantly inhibited cell growth at concentrations of 10 and
20 mM after a 72-h treatment (Figure 1A,B). To evaluate if
the ketone body-induced survival diminution is specific to
cancer cells, we subjected immortalized, non-transformed
pancreatic epithelial cell lines HPNE and RAPAN to incu-
bation with sodium hydroxybutyrate and lithium acetoace-
tate. We observed no significant effect on survival of these
cells under treatment with ketone bodies (Additional file 3).
Similarly, to rule out the possibility of organic acid and lith-
ium ion being responsible for reduction in cancer cell sur-
vival, rather than ketone bodies themselves, we evaluated
the survival of S2-013 and Capan1 under treatment with S-
hydroxy butyric acid and lithium chloride. We observed no
significant effect on S2-013 and Capan1 cell survival after
72 h of treatment (Additional file 4). Furthermore, we
investigated the effect of sodium hydroxybutyrate, lithium
acetoacetate, and S-hydroxybutyrate on intracellular pH.
After 6 h of treatment with different doses of sodium
hydroxybutyrate, lithium acetoacetate, and S-hydroxybuty-
rate on S2-013, Capan1, HPNE, and RAPAN cells, we
observed significant decrease in intracellular pH (0.2 to 0.4
units) in all the cell lines (Additional file 5). Although intra-
cellular acidification upon treatment with ketone bodies
might contribute to the antiproliferative effects of ketone
bodies, it is not the primary cause of cells death as we did
not observe significant cell death upon treatment with S-
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isomer of hydroxybutyrate that caused similar intracellular
pH change as did the other ketone bodies. Furthermore, we
observed a similar effect on intracellular pH in non-
transformed pancreatic epithelial cell lines HPNE and
RAPAN after treatment with sodium hydroxybutyrate, lith-
ium acetoacetate, and S-isomer of hydroxybutyrate but no
significant cell death, as mentioned earlier. Bright-field mi-
croscopy images of the cells treated with 10 and 20 mM of
NaHB and LiAcAc are presented in Figure 1C,D. Further-
more, we investigated the effect of ketone bodies on five
pancreatic cancer cell lines and observed that cell growth
is significantly inhibited in a dose-dependent fashion
(Figure 1E). We also investigated the effect of ketone body
treatment on caspase activity in Capan1 and S2-013 cell
lines. Caspase 3/7 activity increased upon treatment of the
pancreatic cancer cells with ketone bodies in a dose-
dependent manner (Figure 1F).
Ketone bodies cause metabolic alterations in pancreatic
cancer cells
Previous studies indicate that a ketogenic diet induces
metabolic alterations in mice [17]. Hence, we next investi-
gated the effect of ketone bodies on pancreatic cancer cell
metabolism. Because cancer cells demonstrate an increase
in glycolysis [38], we examined the effect of ketone bodies
on glucose uptake and lactate release in Capan1 and S2-
013 cells. Treatment of Capan1 and S2-013 cells with
ketone bodies resulted in a decrease in glucose uptake
(Figure 2A,B) and release of lactate (Figure 2C,D) in a
dose-dependent manner. Since glutamine also supports
pancreatic cancer cell growth [7], we also evaluated the ef-
fect of ketone bodies on glutamine uptake. Our results
indicate a reduced uptake of glutamine by Capan1 and
S2-013 pancreatic cancer cells under treatment with
ketone bodies (Figure 2E,F). Furthermore, we observed a
Figure 1 Ketone bodies inhibit growth and induce apoptosis in pancreatic cancer cell lines. Capan1 (A) and S2-013 (B) cells were treated
with different concentrations of sodium-3-hydroxybutyrate (NaHB) and lithium acetoacetate (LiAcAc) for 72 h, and cell viability was determined
by MTT assay. Bar represents percent viability under indicated treatments relative to treatment with solvent control. Representative bright-field
images of Capan1 (C) and S2-013 (D) cells under treatment with 10- and 20-mM concentrations of NaHB and LiAcAc for 72 h. (E) Multiple
pancreatic cancer cell lines were treated with 10- and 20-mM concentrations of NaHB and LiAcAc for 72 h, and relative cell viability determined
by MTT assay is plotted in the bar charts. (F) Capan1 and S2-013 cells treated with 10- and 20-mM concentrations of sodium-3-hydroxybutyrate
and lithium acetoacetate for 48 h and the relative caspase 3/7 activity are plotted. Values represented are mean ± SEM. *P < 0.05; **P < 0.01.
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reduction in intracellular ATP levels upon treatment with
ketone bodies (Figure 2G,H). Reactive oxygen species
(ROS; a natural by-product of oxidative metabolism) levels
were also downregulated upon treatment with ketone
bodies (Figure 2I,J). Overall, our results indicate that ke-
tone bodies diminish the overall energetic health of pan-
creatic cancer cells by reducing glucose uptake, lactate
release, glutamine uptake, cellular ATP content, and ROS
levels.
Ketone bodies diminish the expression of glycolytic
enzymes
To determine the mechanism of reduced glucose uptake
and lactate release upon treatment of pancreatic cancer
cells with ketone bodies, we next examined if ketone
body-mediated changes were due to alterations in gene
expression levels. We evaluated the expression of genes
encoding glucose transporter-1 (GLUT1) and glycolytic
enzymes hexokinase II (HKII) and lactate dehydrogen-
ase A (LDHA) in ketone body-treated and control cells.
In both Capan1 and S2-013 cells, we observed a reduced
expression of GLUT1 and LDHA but no significant
change in HKII expression (Figure 3A,B) upon treat-
ment with ketone bodies. Furthermore, we analyzed the
protein expression levels of GLUT1 and HKII in S2-013
and Capan1 cells under treatment with ketone bodies or
control. Our results indicate a reduced expression of
GLUT1 but almost no change in HKII levels in cells
treated with ketone bodies (Figure 3C,D). To eliminate
the possibility of non-specific effects of organic acid and
lithium ion on gene expression and metabolism, we de-
termined GLUT1, HKII, and LDHA gene expression
and glucose uptake in S2-013 cells after treatment with
S-hydroxy butyric acid and lithium chloride. We found
a negligible effect of these agents on metabolic gene ex-
pression and glucose uptake (Additional file 6).
Ketone bodies diminish c-Myc expression and activity
Since we observed a downregulation of glucose and glu-
tamine uptake upon treatment with ketone bodies and a
corresponding decrease in glycolytic gene expression, we
next investigated the molecular mechanism behind this de-
crease. Specifically, we evaluated the effect of ketone bodies
on the activity and expression of c-Myc, a common regula-
tor of both glucose and glutamine metabolism [39]. Using
the TFsearch program, the promoter sequences of GLUT1
and LDHA were both found to contain c-Myc binding sites.
Chromatin immunoprecipitation assays were then per-
formed to evaluate the c-Myc occupancy at the GLUT1
and LDHA promoters. Our results indicate a reduced occu-
pancy of c-Myc on GLUT1 and LDHA promoters for
S2-013 cells treated with ketone bodies (Figure 4A,B). Fur-
thermore, we performed real-time PCR to determine the
c-Myc transcript levels in S2-013 and Capan1 cells after
treatment with ketone bodies or control. We observed sig-
nificant reduction in c-Myc expression after treatment with
ketone bodies (Figure 4C,D). We also evaluated c-Myc pro-
tein expression after treatment with ketone bodies and ob-
served a reduction in c-Myc levels in a dose-dependent
manner (Figure 4E,F). To confirm if the alterations in c-
Myc expression were due to altered c-Myc transcription,
we evaluated the transcriptional activity of c-Myc promoter
by utilizing c-Myc promoter-luciferase reporter constructs
[24]. We observed significantly reduced c-Myc promoter
activity under treatment with ketone bodies (Figure 4G).
Altogether, our results demonstrate that the treatment of
pancreatic cells with ketone bodies leads to a reduced c-
Myc expression at mRNA level and a reduced c-Myc occu-
pancy on the GLUT1 and LDHA promoters.
Ketone bodies inhibit tumor cell-induced muscle fiber
and adipocyte degradation in cell-based assays
Malignant cells have been shown to lack key mitochon-
drial enzymes required for metabolizing ketone bodies
to produce ATP, while muscle cells retain this capacity
[18]. Of note, β-hydroxybutyrate improves body weight,
while reducing proteolysis in muscle cells [40]. Hence,
we developed a cell culture-based system to evaluate the
effect of ketone bodies on muscle fibers and adipocyte
adipose deposits under coculture with cancer cells. This
was achieved by differentiating C2C12 premyocytes into
myotubes and 3T3L1 preadipocytes into differentiated
adipocytes. Treatment with Capan1 or S2-013 cancer
cell-conditioned medium (CCCM) induced degradation
of myotubes and depletion of adipose deposits in 3T3L1
adipocytes. Treatment with ketone bodies demonstrated
(See figure on previous page.)
Figure 2 Ketone bodies induce metabolic alterations in pancreatic cancer cell lines. S2-013 (A) and Capan1 (B) cells were treated with
different doses of ketone bodies for 24 h, and glucose uptake was determined by performing 3H-2DG uptake assay. Bars represent counts
normalized with cell number and plotted relative to control. Lactate release was determined by colorimetric assay using culture medium of
S2-013 (C) and Capan1 (D) cells treated with different concentrations of NaHB and LiAcAc for 24 h. Values were normalized with total cell number
and represented relative to controls. S2-013 (E) and Capan1 (F) cells were treated with indicated concentrations of ketone bodies for 24 h, and
glutamine uptake was determined by performing tritiated Glutamine, L-[3,4-3H(N)] uptake assays. Counts were normalized with cell number and
plotted relative to control. ATP levels in S2-013 (G) and Capan1 (H) cells post 24-h treatment with ketone bodies were determined by performing
ATP bioluminescence assays. Values were normalized to total protein concentration and represented relative to control. Reactive oxygen species
level of S2-013 (I) and Capan1 (J) cells under treatment with ketone bodies was determined by utilizing a fluorescence probe, dihydroethidium
(DHE), and fluorescence intensity normalized to cell count was plotted. Values represented are mean ± SEM. *P < 0.05; **P < 0.01.
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a significant protection of myotubes (Figure 5A,B) and
adipocytes (Figure 5D,E) against CCCM. Furthermore,
we analyzed the gene expression levels of muscle-specific
ring finger protein 1 (MuRF1 or Trim63) and Atrogin
(Fbxo32; also known as muscle atrophy F-box protein or
MAFbx) in myotubes, and zinc alpha-2-glycoprotein 1
(Zag or Azgp1) and hormone-sensitive lipase (HSL or
Lipe) in adipocytes treated with CCCM under treatment
with ketone bodies or control. These proteins are upreg-
ulated during cancer-induced cachexia [41]. Ketone
bodies were shown to significantly lower MuRF1 and
Atrogin mRNA levels even in the presence of CCCM
(Figure 5C). We also observed a significant decrease in
Zag and HSL expression upon treatment with ketone
bodies (Figure 5F). Hence, our results indicate the utility
of ketone bodies in inhibiting cancer-induced cachexia.
Ketone bodies alter central carbon metabolism in
pancreatic cancer cells
To evaluate the effect of ketone bodies on metabolite
levels in pancreatic adenocarcinoma cells, we performed a
series of NMR-based metabolomics studies. S2-013 cells
were treated with 20 mM sodium-3-hydroxybutyrate for
24 h, and then a set of 1D 1H NMR spectra were acquired
for cell extracts of sodium-3-hydroxybutyrate-treated or
control S2-013 cells. OPLS-DA of the NMR spectra indi-
cates that the metabolomes from the ketone body-treated
cells and the control cells clustered into two separate
groups in a OPLS-DA score plot, indicating that the
treated cancer cells are metabolically differentiated from
the controls (Figure 6A). The OPLS-DA model was vali-
dated using CV-ANOVA yielding a p value of 8.74 × 10−6
(Additional file 2). The backscaled loadings (Additional
file 7) of the 1D 1H NMR data indicate a reduction in
cellular glutamine and glutamate level. Many cancers are
dependent on glutamine metabolism and have enhanced
glutamine uptake. A significant reduction of choline-
containing compounds is also observed in ketone
body-treated cells. Total choline-containing compound
concentration is typically increased in multiple cancer
phenotypes and referred as a metabolic hallmark of can-
cer. It is particularly noteworthy that ketone body
Figure 3 Ketone bodies repress the expression of key glycolytic enzymes. Relative mRNA expression levels of GLUT1, HKII, and LDHA in Capan1
(A) and S2-013 (B) cells treated with 10- and 20-mM concentrations of NaHB and LiAcAc for 24 h. Total RNA was isolated from NaHB- and
LiAcAc-treated as well as control cells, and relative mRNA levels of different genes were determined by performing qRT-PCR. β-Actin was utilized as an
internal control. Protein expression of GLUT1 and HKII was determined by immunoblotting the total cell lysates from S2-013 (C) and Capan1 (D) cells
treated with 10 and 20 mM NaHB and LiAcAc for 48 h. β-Tubulin was utilized as an internal control. Values shown are mean ± SEM. *P < 0.05;
**P < 0.01.
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treatment appears to reverse these trends [42]. Ketone
body treatment also elevates myo-inositol, taurine, and
alanine. Myo-inositol and its derivative are known to
suppress pancreatic cancer [43].
To further explore the impact of ketone bodies on other
metabolic process, we then labeled the S2-013 metabolome
with 13C6-glucose and compared the cell extracts from
sodium-3-hydroxybutyrate-treated S2-013 cells with control
cells using 2D 1H-13C HSQC NMR experiments. The 2D
1H-13C HSQC spectra identified the 13C-labeled metabolites
in the cell extracts derived from 13C6-glucose. Importantly,
13C6-glucose highlighted metabolite changes associated with
Figure 4 Ketone bodies reduce c-Myc expression and its recruitment to glycolytic gene promoters. Recruitment of c-Myc onto GLUT1
(A) and LDHA (B) promoters in S2-013 cells under treatment with 20 mM NaHB, LiAcAc, or control was confirmed by performing ChIP using
anti-c-Myc Ab and IgG control, followed by qRT-PCR analysis. Relative c-Myc mRNA levels in Capan1 (C) and S2-013 (D) cells treated with 10 and
20 mM NaHB, LiAcAc, or control for 24 h. Total RNA was isolated and relative mRNA level of c-Myc was determined by qRT-PCR. β-Actin was
utilized as an internal control. Capan1 (E) and S2-013 (F) cells were treated with indicated doses of ketone bodies for 48 h, and c-Myc protein
level was determined by immunoblotting the whole cell lysates. HSP90 was used as an internal control. (G) c-Myc-promoter-firefly luciferase
reporter and Renilla luciferase reporter plasmids were transiently transfected into S2-013 cells. After 16 h of transfection, cells were treated with
solvent control or ketone bodies for 24 h. Normalized firefly to Renilla luciferase activity ratio is plotted in the bar chart. Values represented are
mean ± SEM. *P < 0.05; **P < 0.01.
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glycolytic flux in tumor cells. The NMR metabolomics
studies identified multiple metabolites exhibiting statisti-
cally significant concentration changes due to ketone body
treatment (Figure 6B). These identified metabolites were
then incorporated into a network using Cytoscape [44] and
Metscape [45] by linking nearest-neighbor metabolites.
Overall, glucose-derived metabolites involved in glycolysis,
amino acid metabolism, and TCA cycle were altered upon
treatment with ketone bodies (Figure 6C). The 1D 1H load-
ings are also consistent with this general observation. Spe-
cifically, both experiments identify changes in amino acid
metabolism. Again, the ketone bodies are being used as a
Figure 5 Ketone bodies inhibit tumor cell-conditioned medium-induced degradation of myofibers and adipolysis. Differentiated C2C12
cells were treated with S2-013 (A) and Capan1 (B) cell-conditioned medium with or without solvent control and 10 and 20 mM NaHB and LiAcAc
for 72 h, and bright-field images were represented for individual treatments. (C) Differentiated C2C12 cells were cultured in Capan1 and S2-013
cell-conditioned medium with or without ketone body treatment for 24 h. Total RNA was isolated and relative mRNA levels of MuRF1 and Atrogin
were determined by performing qRT-PCR. β-Actin was utilized as an internal control. Differentiated 3T3L1 cells were cultured in S2-013 (D) and
Capan1 (E) cell-conditioned medium with or without ketone body treatment for 72 h and stained with nile red. Fluorescent and bright-field
images for individual treatments are presented. (F) Differentiated 3T3L1 cells were cultured in Capan1 and S2-013 cell-conditioned medium with
or without ketone body treatment for 24 h. Total RNA was isolated and relative mRNA levels of Zag and HSL were determined by qRT-PCR.
β-Actin was utilized as an internal control. Values represented are mean ± SEM. All statistical analyses were conducted with one-way ANOVA with
Dunnett’s post hoc test and CM as the reference group. *P < 0.05; **P < 0.01.
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metabolic substrate and are replacing the cellular need
for glucose and glycolysis. The importance of a detailed
analysis of metabolic changes is highlighted by a key ex-
ample. The 2D 1H-13C HSQC experiments indicate that
the concentrations of glutamate and glutamine derived
from glucose have decreased significantly. Similarly, the
1D 1H loadings indicate that the overall concentrations
of glutamate and glutamine have also decreased upon
ketone body treatment. The metabolites derived from
ketone bodies do not contain a 13C-carbon and are not
detected in the 2D 1H-13C HSQC experiment. Corres-
pondingly, the 1D 1H loadings identify major changes
for unlabeled metabolites that are not visible in a
2D 1H-13C HSQC spectrum. Thus, the 2D 1H-13C
HSQC experiments are complimentary to the 1D 1H ex-
periments and provide a more detailed analysis of a spe-
cific subset of the metabolome.
To study if ketone bodies are getting metabolized by
cancer cells, we treated S2-013 cells with 13C4-labeled hy-
droxyl butyrate and identified its catabolic products by
using a 2D 1H-13C HSQC NMR experiment (Additional
file 8). Because of the low natural abundance of 13C
(1.1%), the only peaks observable in a 2D 1H-13C HSQC
spectrum must originate from the 13C4-labeled hydroxyl
butyrate. As a reference point, the cellular extract was
spiked with 500 μM of TMSP. The single peak originating
from the natural abundant TMSP 13C-methyl groups is
barely detectable in the 2D 1H-13C HSQC spectrum. A
negative control (data not shown), where S2-013 cells
are not treated with a 13C-labeled metabolite, yielded a
null spectrum. Thus, the fact that multiple intense
peaks are observable in the 2D 1H-13C HSQC spectrum
is a clear evidence that the S2-013 cells uptake hydroxyl
butyrate. The 1H and 13C chemical shifts measured
from the 2D 1H-13C HSQC spectrum were then com-
pared against reference NMR spectra available from the
Human Metabolomics Database [32], Madison Metabo-
lomics Consortium Database [33], and Platform for
RIKEN Metabolomics [34] to identify other 13C-labeled
metabolites present in the cell extract. We observed
chemical shifts consistent with 3-hydroxybutyrate, the
original 13C-carbon source, and betaine, N-acetylgluco-
samine, homocarnosine, and succinate, which all must
be catabolic products of 3-hydroxybutyrate.
Inhibiting glycolytic flux in tumor cells prevents cachexia
phenotype in cell line models
Metabolic alterations in cancer cells [46] may contribute
to the secretion of cachectic cytokines and metabolites
involved in cancer-induced cachexia. Based on our find-
ings that ketone bodies mediated a decrease in the ex-
pression of GLUT1 resulting in a metabolic flux, we
evaluated if inhibiting the glycolytic flux alters the cach-
ectic potential in cancer cells. We pretreated S2-013
Figure 6 Ketone bodies modulate metabolite levels in pancreatic cancer cells. (A) OPLS-DA score plot generated from 1D 1H NMR spectra
collected from cell lysates of S2-013 cells (red square) and S2-013 cells treated with 20 mM NaHB (green diamond); each point in the OPLS-DA score plot
represents a single 1D 1H NMR spectrum. Ellipses enclose the 95% confidence intervals estimated by the sample means and covariances of each class.
The leave-n-out cross validation yielded a quality assessment (Q2) value of 0.959 and R2 value of 0.997. The OPLS-DA model was validated using
CV-ANOVA yielding a p value of 8.74 × 10−6. (B) Heat map generated from 2D 1H-13C HSQC NMR spectral data for S2-013 cells. The heat map
represents triplicate measurements of metabolite intensities recorded (*P < 0.1; **P < 0.05; ***P < 0.001). (C) Metabolic pathway depicts 13C carbon flow
from glucose to the intermediates of glycolytic pathway, citric acid cycle, amino acid metabolism, and nucleotide analogues. The arrows represent
relative increase (green arrow up) or decrease (red arrow down) in metabolite concentrations due to ketone body treatment.
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cells with 3-sodium hydroxybutyrate, lithium acetoace-
tate, or glycolytic inhibitor 3-bromopyruvic acid (BPA)
and then collected the conditioned medium and evalu-
ated the cachectic potential by utilizing C2C12 myotube
and 3T3L1 adipocyte systems. We also assayed condi-
tioned medium from GLUT1 knockdown S2-013 cells
(S2-013-shGLUT1) for cachectic potential. Treatment
with conditioned medium generated from ketone bodies
or glycolytic inhibitor-pretreated S2-013 cells, or GLUT1
knockdown S2-013 cells, demonstrated a significant pro-
tection against myotube degradation (Figure 7A,B) and
adipocyte fat depletion (Figure 7C,D) in comparison to
controls. Furthermore, we analyzed the gene expression
levels of MuRF1 and Atrogin in myotubes and Zag and
HSL in adipocytes treated with the above-described
CCCM. We observed a significant reduction of MuRF1
and Atrogin gene expression in C2C12 myotubes under
treatment with CCCM from ketone body or inhibitor-
pretreated cells, or GLUT1 knockdown cell-derived
conditioned media, in comparison to control CCCM-
treated myotubes (Figure 7E). Similarly, we observed
a reduced expression of Zag and HSL in 3T3L1 adi-
pocytes in the presence of pretreated CCCM in com-
parison to the controls (Figure 7F). To ensure the
inhibition of glycolysis by BPA and GLUT1 knock-
down, we performed glucose uptake assay in S2-013
cells treated with BPA or solvent control as well
as S2-013-shGLUT1 and S2-013-shScr cells. We ob-
served a significant reduction in glucose uptake under
these conditions (Additional file 9). As we observed
that ketone bodies act like metabolic inhibitors, we
further explored if glycolytic product lactate and
alanine, which could be secreted into the medium, in
CCCM could abrogate the effect of ketone body treat-
ment of tumor cells on the expression of cachectic
markers in adipocytes and myotubes. We observed no
significant alteration in cachectic marker expression
after adding lactate or alanine (Additional file 9),
Figure 7 Pretreatment of tumor cells with ketone bodies or glycolytic inhibition diminishes their cachectic potential. S2-013 cells were
treated with solvent control, 20 mM NaHB (NaHB-S2-013), 20 mM LiAcAc (LiAcAc-S2-013), and 10 μM 3-bromopyruvic acid (BPA-S2-013) for 24 h. The
cells were then washed twice with phosphate-buffered saline and cultured in serum-free DMEM. After 24 h, the conditioned medium was collected.
The conditioned medium was also prepared from GLUT1 knockdown S2-013 (S2-013-shGLUT1) and control cells (S2-013-shScr). Differentiated
myotubes from C2C12 cells were cultured in (A) control, S2-013-CM, NaHB-S2-013-CM, LiAcAc-S2-013-CM, and BPA-S2-013-CM or (B) control,
S2-013-shScr-CM, and S2-013-shGLUT1-CM for 72 h, and bright-field images were represented for individual treatments. Differentiated 3T3L1 cells were
cultured in (C) control, S2-013-CM, NaHB-S2-013-CM, LiAcAc-S2-013-CM, and BPA-S2-013-CM or (D) control, S2-013-shScr-CM, and S2-013-shGLUT1-CM
for 72 h and stained with nile red, and images for individual treatments are represented. (E) Differentiated myotube form C2C12 cells were cultured in
similar conditions for 24 h. Total RNA was isolated and relative mRNA levels of MuRF1 and Atrogin were determined by qRT-PCR. β-Actin was utilized
as an internal control. (F) Differentiated 3T3L1 cells were cultured in the above-mentioned conditions for 24 h. Total RNA was isolated and relative
mRNA levels of Zag and HSL were determined by qRT-PCR. β-Actin was utilized as an internal control. Values represented are mean ± SEM. All statistical
analyses were conducted with one-way ANOVA with Dunnett’s post hoc test and S2-013-CM as the reference group.*P < 0.05; **P < 0.01.
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which indicates that these metabolic by-products are
not solely responsible for the cachectic phenotype.
A ketogenic diet reduces tumor growth and cachectic
phenotype in animal models
To determine the effect of a ketogenic diet on tumor
growth, we implanted S2-013 pancreatic cancer cells ortho-
topically into the pancreas of athymic nude mice. One week
later, S2-013 cell-implanted mice were fed ad libitum on a
ketogenic diet or normal chow for 3 weeks. After 3 weeks
on the diets, mice were sacrificed and tumor weight, tumor
volume, muscle weight, and carcass weight were recorded.
S2-013 tumor-bearing mice fed on the ketogenic diet
demonstrated reduced tumor weight and tumor volume
(Figure 8A,B). The ketogenic diet also reduced desmoplasia
as observed by Masson’s trichrome stain (Figure 8C). Fur-
thermore, we investigated the effect of the ketogenic diet
on tumor cell proliferation and apoptosis by immunohisto-
chemically staining the tumor sections for Ki67 and cleaved
caspase 3, respectively. We observed that the ketogenic diet
reduced tumor cell proliferation and increased apoptosis as
indicated by the decreased percentage of cells with Ki67-
positive staining and increased staining for cleaved caspase
3, in comparison to the tumors from mice fed on a control
Figure 8 A ketogenic diet reduces tumor growth and proliferation and reverts the cachectic phenotype. Into the pancreas of athymic
nude mice, 0.5 × 106 S2-013 cells were orthotopically implanted. After 1 week of implantation, mice were divided in two groups and fed with
either a control diet or a ketogenic diet. Three weeks post treatment, mice were sacrificed and tumor weight (A) and tumor volume (B) were
measured. (C) Masson’s trichrome staining (blue stain indicates desmoplastic region) and immunohistochemistry images from the control diet
and the ketogenic diet-fed mice tumor sections. (D) Blood glucose and ketone levels in the control and the ketogenic diet-fed mice before
necropsy. (E) Muscle weight and carcass weight of the control and the ketogenic diet-fed mice. (F) Immunohistochemistry of c-Myc in the
control and the ketogenic diet-fed mice tumor sections. Values shown are mean ± SEM. *P < 0.05; **P < 0.01.
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chow (Figure 8C). Blood glucose levels were also lower in
the ketogenic diet-fed mice, while the ketone body levels
(β-hydroxybutyrate) were significantly higher in the same
group (Figure 8D). Furthermore, we performed NMR ana-
lysis to determine the levels of ketone bodies in plasma and
tumor tissues from control and ketogenic diet-fed mice.
We observed an approximately twofold increase of ketone
body (β-hydroxybutyrate) concentration in tumor tissue
(range 0.85–7.84 mM) in comparison to plasma (range
0.47–3.13 mM), as shown in Additional file 10. The differ-
ence between tumoral ketone body levels in ketogenic diet-
fed and normal diet-fed mice was also very striking
(Additional file 11), as observed by NMR. Furthermore, we
investigated muscle weight and carcass weight as markers
of cancer-induced cachexia in the control or the ketogenic
diet-fed tumor-bearing mice. We observed a 45% increase
in the muscle weight and a 20% increase in the carcass
weight in ketogenic diet-fed mice in comparison to the con-
trols (Figure 8E). We also evaluated c-Myc expression in
tumor sections from control or ketogenic diet-fed mice. As
expected from our cell culture-based studies, we observed
reduced tumoral c-Myc expression in the ketogenic diet-
fed mice (Figure 8F). Overall, our results indicate that a ke-
togenic diet diminishes tumor growth and proliferation in
mice and inhibits cancer-induced cachexia.
Discussion
Metabolism plays a very important role in cellular func-
tion and cell survival. Altered cell metabolism is a hall-
mark of cancer [6]. Cellular proliferation is directly
dependent on nutrient availability, and most mitogenic
signals exert their influence on cell proliferation by regu-
lating nutrient uptake and synthesis of DNA, RNA,
protein, and lipids [46]. It has been shown that enhanced
glucose uptake supports the production of intermediates
required for biomass production in proliferating cancer
cells. In addition, cancer cells also demonstrate altered
glutamine uptake and glutaminolysis, which replenish in-
termediates of tricarboxylic acid cycle and play an import-
ant role in the biosynthetic processes [47]. Our present
studies indicate that ketone bodies revert metabolic adap-
tations in pancreatic cancer cells to induce growth arrest
and apoptosis. Our results indicate a reduction in glucose
uptake, glycolytic flux, glutamine uptake, lactate secretion,
and ATP content in pancreatic cancer cells after treatment
with ketone bodies. The reversal of metabolic syndrome
in cancer cells by ketone bodies might be related to levels
of c-Myc. Furthermore, we demonstrate that metabolic re-
programming of tumor cells by ketone bodies is respon-
sible for diminishing cancer cell-induced cachexia in cell
line models and animal models of pancreatic cancer.
Oxidative stress plays an important role in cancer pro-
gression, which results from an imbalance between the
production of reactive oxygen species (ROS) and the
cellular antioxidant defenses. ROS deregulates the redox
homeostasis and promotes several inflammatory path-
ways leading to tumor formation [48]. Since ketone
bodies were shown to diminish cellular glucose and glu-
tamine flux, we also investigated if ketone bodies would
diminish cellular ROS levels. We observed a reduction
in ROS levels after treatment with ketone bodies. Of note,
the anticancerous property of several phytochemicals and
dietary compounds is mediated by their antioxidant activ-
ity [48]. Recent studies indicate that β-hydroxybutyrate,
the main ketone body found in the body, reduces oxida-
tive stress [49] and, in turn, functions as a histone deacety-
lase inhibitor. Inhibition of histone deacetylase activity
can suppress or prevent cancer growth as indicated by
several studies with histone deacetylase inhibitors that are
currently being evaluated for cancer prevention [50].
Most tumors are highly dependent on glucose as an
energy source. For the same reason, several inhibitors of
glycolysis have been extensively evaluated in preclinical
cancer models [51]. We observed a reduced expression
of glucose transporter GLUT1 and glycolytic enzyme
LDHA in pancreatic cancer cells upon treatment with
ketone bodies (Figure 3). Inhibition of GLUT1, which is
the main transporter of glucose in cancer cells, is cur-
rently being considered for cancer therapy [52]. Also,
LDHA inhibition causes reduced cancer cell prolifera-
tion [47]. Furthermore, this present study indicates that
ketone bodies diminish c-Myc expression and its occu-
pancy on glycolytic gene promoters. c-Myc is an import-
ant regulator of cell growth and proliferation [39]. In
transformed cells, c-Myc enhances the expression of
glycolytic genes GLUT1, LDHA, and ENO1 as well as
glutaminolytic genes such as GLS [53,54]. c-Myc is
considered an attractive therapeutic target due to its role
in modulating cell metabolism, tumor initiation, and
growth in a variety of cancer types [53]. Hence, reduced
c-Myc expression by ketone bodies might contribute to
the growth inhibitory effects of ketone bodies in pancre-
atic cancer. Previously, it has been reported that c-Myc
inhibition leads to regression of lung cancer [55], blad-
der cancer [56], and pancreatic cancer [57].
Cachexia affects a majority of pancreatic cancer pa-
tients and significantly contributes to morbidity and
mortality [3]. However, agents targeting cachexia remain
largely elusive. Metabolic adaptations in tumor cells are
primarily responsible for the muscle weight loss and the
depletion of adipose deposits associated with cachexia.
Our study identifies ketone bodies as therapeutic agents
that can diminish cancer cachexia by deactivating meta-
bolic adaptations in cancer cells. Herein, we described
cell culture-based models for investigating agents target-
ing cancer cachexia that is a corollary to our animal
models of pancreatic cancer cachexia. Our results with
the cell culture-based models indicate that ketone bodies
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significantly inhibit myotube degradation and adipolysis.
We also observed a reduced expression of MuRF1, Atro-
gin, Zag, and HSL, which are signature genes associated
with cachexia (Figure 5). Thus, ketone bodies inhibit
pancreatic cancer cell growth along with inhibition of
pancreatic cancer-associated cachexia. Our NMR-based
metabolomics studies indicate that treatments with ke-
tone bodies significantly alter the metabolite flux in pan-
creatic cancer cells. We observed reduced cellular levels
of glutamine, which is the most abundant amino acid
and is involved in the regulation of growth and prolifera-
tion of cells. Cancer cell proliferation significantly de-
pends on glutamine availability [13], and hence, the
growth inhibitory effects of ketone bodies might in part
be mediated by glutamine availability. Increased proline
and lysine levels might play a role in growth inhibition
of pancreatic cancer cells. Growth inhibitory effects of
proline and lysine are known in bladder cancer cells
[58]. We also observed an accumulation of the TCA me-
tabolite citrate, which inhibits the phosphofructokinase
enzyme in the glycolysis pathway and induces apoptosis
in cancer cells [57]. Altogether, the metabolic shift after
treatment of ketone bodies might significantly contribute
to growth inhibition and apoptosis in cancer cells.
Although a link has been suggested between the meta-
bolic needs of the growing tumor and cachexia syndrome,
no studies have evaluated such a relationship. Our studies,
for the first time, have confirmed that the metabolic re-
quirements of growing tumor cells are directly responsible
for the muscle degradation and lipolysis that are funda-
mental to the cachexia syndrome. Our results indicate
that the inhibition of either glucose uptake by GLUT1
knockdown or chemical inhibition of glycolysis by utiliz-
ing BPA in cancer cells diminished myotube degradation
and depletion of adipose deposits. Hence, our findings
underscore the significance of tumor cell glucose metabol-
ism in facilitating tumor-associated cachexia.
We observed increased concentration of ketone bodies
in tumor cells in comparison to plasma; however, we did
not explore any concentrative transport mechanisms. For
in vitro studies, we utilized 10- and 20-mM concentra-
tions of ketone bodies that are higher than physiological
levels in plasma, but these are somewhat comparable to
the concentrations in tumor cells in vivo (ranging from
0.85 to 7.84 mM; average 2.41 mM), in mice fed with a ke-
togenic diet. Furthermore, using similar concentrations,
we observed no significant alteration in viability of non-
transformed pancreatic ductal epithelial cells (Additional
file 2). It indicates that the utilized doses do not affect
non-cancer cell survival. In addition, our experiments in-
dicate that ketone bodies do get metabolized in tumor
cells that would further diminish actual concentration of
ketone bodies in the tissues. The need for higher levels of
ketone bodies in cell culture conditions to have biological
efficacy might in part be due to higher glucose levels in the
culture conditions (25 mM) than the physiological concen-
tration (5.5 mM; even lower in tumor-bearing mice).
Hence, if the effects of ketone bodies are simply due to de-
creased tumoral glucose levels, it is expected that the cell
culture conditions would require higher doses. Regardless,
the discrepancy in the levels of ketone bodies required to
achieve the biological effects in culture conditions and in
mice models reflects the inherent differences in the two ex-
perimental systems.
Diet is a key player in the progression and pathogen-
esis of cancer. While high-calorie and high-fat diets are
associated with increased incidence of cancer [59],
several epidemiological studies have demonstrated a dir-
ect relationship between low-sugar diet and a lower in-
cidence of cancer [60]. Our study indicates a reduced
tumor growth and tumor weight, along with a reduced
proliferation of tumor cells in tumor-bearing mice that
were subjected to a ketogenic diet relative to regular
chow. Overall, along with a reduced tumor burden, the
ketogenic diet also improved muscle mass and body
weight in tumor-bearing mice. Hence, a ketogenic diet
may serve as an anticancer agent as well as an antica-
chectic agent.
Conclusions
Metabolic alterations, being a hallmark of cancer, can be
utilized to target different aspects of tumor growth or
associated phenotypes. Cancer cachexia is associated
with significant mortality in pancreatic cancer patients.
In the present study, we investigated a novel systemic
approach to modulate pancreatic cancer cell metabol-
ism for diminishing tumor cell survival and ameliorating
cancer cachexia. We have demonstrated anticancerous
and anticachectic properties of ketone bodies in cell cul-
ture conditions, as well as the effect of a ketogenic diet
on tumor burden and cachexia in animal models. Fur-
thermore, our studies establish a ketone body-induced
metabolomics reprogramming as the mechanism of ac-
tion of a ketogenic diet against cancer and cancer-
induced cachexia.
Additional files
Additional file 1: (A) Sequence of qRT-PCR primers. (B) Composition
of ketogenic diet [RESEARCH DIETS D10082502].
Additional file 2: OPLS-DA analysis. (A) Validation model of a 1000
random permutation test for the OPLS-DA model. (B) RQ plot for the
OPLS-DA model. R2 = 0.95863, Q2 = 0.95863.
Additional file 3: Effect of sodium hydroxybutyrate and lithium
acetoacetate on non-transformed cells survival. (A) HPNE and (B)
RAPAN cells (hTERT-immortalized pancreatic epithelial cell lines) were
treated with different concentrations of sodium- 3-hydroxybutyrate
(NaHB) and lithium acetoacetate (LiAcAc) for 72 h and cell viability was
determined by MTT assay.
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Additional file 4: Effect of S-hydroxybutyrate and lithium chloride
on pancreatic cancer cell survival. S2-013 (A) and Capan 1 (B) cells
were treated with S-hydroxy butyric acid (SHB) and LiCl for 72 h, and cell
viability was determined by MTT assay.
Additional file 5: Effect of sodium hydroxybutyrate and lithium
acetoacetate on intracellular pH. S2-013 (A), Capan1 (B), HPNE (C), and
RAPAN (D) cells were treated with different doses of NaHB, LiAcAc, and
SHB for 6 h, and pH was determined by using BCPCF-AM dye.
Additional file 6: Effect of S-hydroxy butyric acid and LiCl on gene
expression and glucose uptake. (A) Relative mRNA expression levels of
GLUT1, HKII, and LDHA in S2-013 cells treated with 10- and 20-mM
concentrations of SHB and LiCl for 24 h. Beta-actin was used as internal
control. (B) S2-013 cells were treated with 10- and 20-mM concentrations
of SHB and LiCl for 24 h, and glucose uptake was measured by using
3H-2DG uptake.
Additional file 7: Backscale plot generated from OPLS-DA scores.
The red color peaks are spectral regions that have higher contribution for
class separation. The positive and negative peaks represent metabolites
that increased in S2-013 cells and S2-013 cells treated with 20 mM NaHB,
respectively.
Additional file 8: Ketone bodies are metabolized by pancreatic
cancer cells. 2D 1H-13C HSQC spectrum collected on the metabolome
extracted from S2-013 cells after treatment with 20 mM 13C4-labeled
3-hydroxybutyrate (3-HB).
Additional file 9: Metabolic inhibition in tumor cells and cachectic
marker expression in myotubes and adipocytes. (A) S2-013 cells were
treated with different doses of BPA for 24 h, and glucose uptake was
determined by performing 3H-2DG uptake assay. (B) Glucose uptake was
determined by performing 3H-2DG uptake assays in S2-013-shScr and
S2-013-shGLUT1 after 24 h of seeding. S2-013 cells were treated with
solvent control, 20 mM NaHB (NaHB-S2-013), and 20 mM LiAcAc
(LiAcAc-S2-013) for 24 h. The cells were then washed twice with
phosphate-buffered saline and cultured in serum-free DMEM. After 24 h,
the conditioned medium was collected. (C) Differentiated 3T3L1 cells
were cultured in the mentioned conditions for 24 h along with lactate
(2 mM) and alanine (2 mM). Total RNA was isolated and relative mRNA
levels of HSL and Zag were determined by qRT-PCR. β-Actin was utilized
as an internal control. (D) Differentiated myotube form C2C12 cells were
cultured in similar conditions for 24 h along with lactate (2 mM) and
alanine (2 mM). Total RNA was isolated and relative mRNA levels of
MuRF1 and Atrogin were determined by qRT-PCR. β-Actin was utilized as
an internal control.
Additional file 10: 3-Hydroxybutyrate levels in plasma and tumor
specimens from ketogenic diet-fed mice. Plasma and tumor tissue
metabolites were extracted by methanol extraction and the levels of
3-hydroxybutyrate were determined by NMR analysis. The exact
concentrations were calculated by generating a standard curve for
multiple concentrations of 3-hydroxybutyrate.
Additional file 11: Representative 1H NMR spectra for 140 mg of
tumor extracts from normal diet- and ketogenic diet-fed mice. Tumors
were homogenized and metabolites were extracted using 80%
cryogenically cold methanol and water. Peak represents methyl peaks of
3-hydroxybutyrate. Dashed line represents 3-hydroxybutyrate in ketogenic
diet-fed mice and solid line represents the same from normal diet-fed mice.
Abbreviations
BPA: 3-bromopyruvic acid; CCCM: cancer cell-conditioned medium;
DG: 2-deoxyglucose; DHE: dihydroethidium; GLUT1: glucose transporter-1;
HKII: hexokinase II; HSL: hormone sensitive lipase; HSQC: hetero-nuclear
single quantum coherence; IBMX: methylisobutylxanthine; IFN-γ: interferon
gamma; IL-6: interleukin-6; LDHA: lactate dehydrogenase A; LiAcAc: lithium
acetoacetate; MAFbx: muscle atrophy F-box protein; MTT: 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Murf1: muscle-specific
ring finger protein 1; NaHB: 3-hydroxybutyrate; OPLS-DA: orthogonal
projections to latent structures discriminant analysis; PDAC: pancreatic ductal
adenocarcinoma; ROS: reactive oxygen species; TMSP: 3-(tetramethysilane)
propionic acid-2,2,3,3-d4; TNFα: tumor necrosis factor alpha; Zag:
zinc alpha-2-glycoprotein 1.
Competing interests
The authors have declared that no competing interests exist.
Authors’ contributions
SKS designed the experiments; performed experiments with cell culture,
animal models, and metabolomics studies; and drafted the manuscript. TG
performed metabolomics studies. VP performed the animal studies. NVC
carried out cell culture studies. VG performed metabolomics studies. PR
assisted with the animal studies. KM conceived the study and helped draft
the manuscript. IIP participated in the design of the study and helped draft
the manuscript. RP designed and supervised metabolomics studies. FY
performed and advised for the statistical analyses. PKS participated in its
design, execution, and coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We would like to thank Tom Dao for assistance with imaging. This work was
supported in part by funding from the National Institutes of Health grants
(P20 RR-17675, P30 GM103335, R01 CA163649) to PKS and RP, American
Association for Cancer Research (AACR)—Pancreatic Cancer Action Network
(PanCAN) Career Development Award (30-20-25-SING) to PKS, the Specialized
Programs for Research Excellence (SPORE, P50 CA127297, NCI) Career
Development Award to PKS, SPORE (P50 CA127297, NCI) Developmental
Research Project Award to PKS, Pancreatic Tumor Microenvironment
Research Network (U54, CA163120, NCI) to PKS, LB506 (2014–37, DHHS-NE)
to PKS, and Cancer Prevention and Control Nutrition seed grant (15618,
GSCN) to PKS. The research was performed in facilities renovated with
support from the National Institutes of Health (RR015468-01).
Author details
1The Eppley Institute for Research in Cancer and Allied Diseases, University of
Nebraska Medical Center, Omaha, NE 68198, USA. 2Department of Chemistry,
University of Nebraska—Lincoln, Lincoln, NE 68588, USA. 3Department of
Pathology and Microbiology, University of Nebraska Medical Center, Omaha,
NE 68198, USA. 4Department of Cellular and Integrative Physiology,
University of Nebraska Medical Center, Omaha, NE 68198, USA. 5Department
of Surgery, University of Nebraska Medical Center, Omaha, NE 68198, USA.
6Department of Biostatistics, University of Nebraska Medical Center, Omaha,
NE 68198, USA. 7Department of Biochemistry and Molecular Biology,
University of Nebraska Medical Center, Omaha, NE 68198, USA. 8Department
of Genetic Cell Biology and Anatomy, University of Nebraska Medical Center,
Omaha, NE 68198, USA.
Received: 23 January 2014 Accepted: 11 August 2014
Published: 1 September 2014
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 2010, 362:1605–1617.
3. Muliawati Y, Haroen H, Rotty LW: Cancer anorexia—cachexia syndrome.
Acta Med Indones 2012, 44:154–162.
4. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2002, 2:862–871.
5. Inui A: Cancer anorexia-cachexia syndrome: current issues in research
and management. CA Cancer J Clin 2002, 52:72–91.
6. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2012, 144:646–674.
7. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone
CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM,
Haigis MC, DePinho RA, Cantley LC, Kimmelman AC: Glutamine supports
pancreatic cancer growth through a KRAS-regulated metabolic pathway.
Nature 2013, 496:101–105.
8. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond.
Cell 2008, 134:703–707.
9. Lunt SY, Vander Heiden MG: Aerobic glycolysis: meeting the metabolic
requirements of cell proliferation. Annu Rev Cell Dev Biol 2011, 27:441–464.
10. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK,
Mueller-Klieser W: High lactate levels predict likelihood of metastases,
tumor recurrence, and restricted patient survival in human cervical
cancers. Cancer Res 2000, 60:916–921.
Shukla et al. Cancer & Metabolism 2014, 2:18 Page 17 of 19
http://www.cancerandmetabolism.com/content/2/1/18
11. Shaw RJ: Glucose metabolism and cancer. Curr Opin Cell Biol 2006,
18:598–608.
12. Tayek JA: A review of cancer cachexia and abnormal glucose metabolism
in humans with cancer. J Am Coll Nutr 1992, 11:445–456.
13. DeBerardinis RJ, Cheng T: Q’s next: the diverse functions of glutamine in
metabolism, cell biology and cancer. Oncogene 2010, 29:313–324.
14. Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM: The efficacy
of the ketogenic diet-1998: a prospective evaluation of intervention in
150 children. Pediatrics 1998, 102:1358–1363.
15. Masino SA, Geiger JD: Are purines mediators of the anticonvulsant/
neuroprotective effects of ketogenic diets? Trends Neurosci 2008,
31:273–278.
16. Ruskin DN, Kawamura M, Masino SA: Reduced pain and inflammation in
juvenile and adult rats fed a ketogenic diet. PLoS One 2009, 4:e8349.
17. Kennedy AR, Pissios P, Otu H, Roberson R, Xue B, Asakura K, Furukawa N,
Marino FE, Liu FF, Kahn BB, Libermann TA, Maratos-Flier E: A high-fat,
ketogenic diet induces a unique metabolic state in mice. Am J Physiol
Endocrinol Metab 2007, 292:E1724–E1739.
18. Klement RJ, Kammerer U: Is there a role for carbohydrate restriction in
the treatment and prevention of cancer? Nutr Metab (Lond) 2011, 8:75.
19. Freeman JM, Kossoff EH, Hartman AL: The ketogenic diet: one decade
later. Pediatrics 2007, 119:535–543.
20. Hashim SA, Vanitallie TB: Ketone body therapy: from ketogenic diet to
oral administration of ketone ester. J Lipid Res 2014, in press.
21. Iwamura T, Taniguchi S, Kitamura N, Yamanari H, Kojima A, Hidaka K,
Setoguchi T, Katsuki T: Correlation between CA19-9 production in vitro
and histological grades of differentiation in vivo in clones isolated from
a human pancreatic cancer cell line (SUIT-2). J Gastroenterol Hepatol 1992,
7:512–519.
22. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative
CT method. Nat Protoc 2008, 3:1101–1108.
23. Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K,
Gendler SJ, Bennett EP, Hollingsworth MA: Phosphorylation of MUC1 by
Met modulates interaction with p53 and MMP1 expression. J Biol Chem
2008, 283:26985–26995.
24. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ,
Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC
pathway. Science 1998, 281:1509–1512.
25. Behrens ME, Grandgenett PM, Bailey JM, Singh PK, Yi CH, Yu F,
Hollingsworth MA: The reactive tumor microenvironment: MUC1
signaling directly reprograms transcription of CTGF. Oncogene 2010,
29:5667–5677.
26. Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X,
Zhang B, Mehla K, Brown RB, Caffrey T, Yu F, Johnson KR, Powers R,
Hollingsworth MA, Singh PK: MUC1 mucin stabilizes and activates
hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic
cancer. Proc Natl Acad Sci U S A 2011, 109:13787–13792.
27. Nguyen BD, Meng X, Donovan KJ, Shaka AJ: SOGGY: solvent-optimized
double gradient spectroscopy for water suppression. A comparison with
some existing techniques. J Magn Reson 2007, 184:263–274.
28. Worley B, Powers R: MVAPACK: a complete data handling package for
NMR metabolomics. ACS Chem Biol 2014, 9:1138–1144.
29. De Meyer T, Sinnaeve D, Van Gasse B, Tsiporkova E, Rietzschel ER, De
Buyzere ML, Gillebert TC, Bekaert S, Martins JC, Van Criekinge W: NMR-
based characterization of metabolic alterations in hypertension using an
adaptive, intelligent binning algorithm. Anal Chem 2008, 80:3783–3790.
30. Halouska S, Zhang B, Gaupp R, Lei S, Snell E, Fenton RJ, Barletta RG,
Somerville GA, Powers R: Revisiting protocols for the NMR analysis of
bacterial metabolomes. J Integrated OMICS 2013, 3:120–137.
31. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A: NMRPipe: a
multidimensional spectral processing system based on UNIX pipes.
J Biomol NMR 1995, 6:277–293.
32. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y,
Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P,
Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R,
Scalbert A: HMDB 3.0—the human metabolome database in 2013.
Nucleic Acids Res 2013, 41:D801–D807.
33. Cui Q, Lewis IA, Hegeman AD, Anderson ME, Li J, Schulte CF, Westler WM,
Eghbalnia HR, Sussman MR, Markley JL: Metabolite identification via the
Madison Metabolomics Consortium Database. Nat Biotechnol 2008,
26:162–164.
34. Akiyama K, Chikayama E, Yuasa H, Shimada Y, Tohge T, Shinozaki K, Hirai
MY, Sakurai T, Kikuchi J, Saito K: PRIMe: a web site that assembles tools for
metabolomics and transcriptomics. In Silico Biol 2008, 8:339–345.
35. Xi Y, de Ropp JS, Viant MR, Woodruff DL, Yu P: Improved identification of
metabolites in complex mixtures using HSQC NMR spectroscopy.
Anal Chim Acta 2008, 614:127–133.
36. Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S: Bioinformatics and
Computational Biology Solutions Using R and Bioconductor. In Statistics
for Biology and Health, vol XIX. Edited by Wong W, Gail M, Krickeberg K,
Tsiatis A, Samet J. Springer; 2005:3–12.
37. Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X,
Hagg M, Linder S, Fais S, Codogno P, De Milito A: Autophagy is a protect-
ive mechanism for human melanoma cells under acidic stress. J Biol
Chem 2012, 287:30664–30676.
38. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the
Warburg effect: the metabolic requirements of cell proliferation.
Science 2009, 324:1029–1033.
39. Dang CV: MYC on the path to cancer. Cell 2012, 149:22–35.
40. Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ: Signaling pathways
initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depres-
sion of protein synthesis in skeletal muscle in response to cachectic
stimuli. Am J Physiol Endocrinol Metab 2007, 293:E923–E931.
41. Fearon KC, Glass DJ, Guttridge DC: Cancer cachexia: mediators, signaling,
and metabolic pathways. Cell Metab 2012, 16:153–166.
42. Glunde K, Bhujwalla ZM, Ronen SM: Choline metabolism in malignant
transformation. Nat Rev Cancer 2011, 11:835–848.
43. Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M:
Myo-inositol trispyrophosphate-mediated hypoxia reversion controls
pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J
Cancer 2014, 134:2572–2582.
44. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N,
Schwikowski B, Ideker T: Cytoscape: a software environment for
integrated models of biomolecular interaction networks. Genome Res
2003, 13:2498–2504.
45. Gao J, Tarcea VG, Karnovsky A, Mirel BR, Weymouth TE, Beecher CW,
Cavalcoli JD, Athey BD, Omenn GS, Burant CF, Jagadish HV: Metscape: a
Cytoscape plug-in for visualizing and interpreting metabolomic data in
the context of human metabolic networks. Bioinformatics 2010,
26:971–973.
46. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB: Brick by brick:
metabolism and tumor cell growth. Curr Opin Genet Dev 2008, 18:54–61.
47. Schulze A, Harris AL: How cancer metabolism is tuned for proliferation
and vulnerable to disruption. Nature 2012, 491:364–373.
48. Acharya A, Das I, Chandhok D, Saha T: Redox regulation in cancer: a
double-edged sword with therapeutic potential. Oxid Med Cell Longev
2010, 3:23–34.
49. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter
CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R,
Ulrich S, Akassoglou K, Verdin E: Suppression of oxidative stress by β-
hydroxybutyrate, an endogenous histone deacetylase inhibitor.
Science 2013, 339:211–214.
50. Shabason JE, Tofilon PJ, Camphausen K: HDAC inhibitors in cancer care.
Oncology (Williston Park) 2010, 24:180–185.
51. Tennant DA, Duran RV, Gottlieb E: Targeting metabolic transformation for
cancer therapy. Nat Rev Cancer 2010, 10:267–277.
52. Amann T, Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular
carcinoma. Expert Opin Ther Targets 2009, 13:1411–1427.
53. Gordan JD, Thompson CB, Simon MC: HIF and c-Myc: sibling rivals for control
of cancer cell metabolism and proliferation. Cancer Cell 2007, 12:108–113.
54. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R,
Dang CV: c-Myc transactivation of LDH-A: implications for tumor metab-
olism and growth. Proc Natl Acad Sci U S A 1997, 94:6658–6663.
55. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis
AN, Swigart LB, Nasi S, Evan GI: Modelling Myc inhibition as a cancer
therapy. Nature 2008, 455:679–683.
56. Jeong KC, Kim KT, Seo HH, Shin SP, Ahn KO, Ji MJ, Park WS, Kim IH, Lee SJ,
Seo HK: Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses
orthotopic bladder tumor growth. J Urol 2013, 191:510–518.
57. Lu Y, Zhang X, Zhang H, Lan J, Huang G, Varin E, Lincet H, Poulain L, Icard
P: Citrate induces apoptotic cell death: a promising way to treat gastric
carcinoma? Anticancer Res 2013, 31:797–805.
Shukla et al. Cancer & Metabolism 2014, 2:18 Page 18 of 19
http://www.cancerandmetabolism.com/content/2/1/18
58. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M: Antitumor effect
of ascorbic acid, lysine, proline, arginine, and green tea extract on
bladder cancer cell line T-24. Int J Urol 2006, 13:415–419.
59. Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC: Diet,
nutrition and the prevention of cancer. Public Health Nutr 2004, 7:187–200.
60. Willcox DC, Willcox BJ, Todoriki H, Suzuki M: The Okinawan diet: health
implications of a low-calorie, nutrient-dense, antioxidant-rich dietary
pattern low in glycemic load. J Am Coll Nutr 2009, 28(Suppl):500S–516S.
doi:10.1186/2049-3002-2-18
Cite this article as: Shukla et al.: Metabolic reprogramming induced by
ketone bodies diminishes pancreatic cancer cachexia. Cancer &
Metabolism 2014 2:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Shukla et al. Cancer & Metabolism 2014, 2:18 Page 19 of 19
http://www.cancerandmetabolism.com/content/2/1/18
CORRECTION Open Access
Correction: Metabolic reprogramming induced by
ketone bodies diminishes pancreatic cancer
cachexia
Surendra K Shukla1, Teklab Gebregiworgis2, Vinee Purohit1,3, Nina V Chaika1, Venugopal Gunda1,
Prakash Radhakrishnan1, Kamiya Mehla1, Iraklis I Pipinos4,5, Robert Powers2, Fang Yu6 and Pankaj K Singh1,3,7,8*
Correction
After publication of this Research Article [1], we noticed
we had included an incorrect image in Figure 1D in
the panel for LiAcAc 20 mM. A corrected Figure 1 is
included here.
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Figure 1 Ketone bodies inhibit growth and induce apoptosis in pancreatic cancer cell lines. Capan1 (A) and S2-013 (B) cells were treated
with different concentrations of sodium-3-hydroxybutyrate (NaHB) and lithium acetoacetate (LiAcAc) for 72 h, and cell viability was determined
by MTT assay. Bar represents percent viability under indicated treatments relative to treatment with solvent control. Representative bright-field
images of Capan1 (C) and S2-013 (D) cells under treatment with 10- and 20-mM concentrations of NaHB and LiAcAc for 72 h. (E) Multiple
pancreatic cancer cell lines were treated with 10- and 20-mM concentrations of NaHB and LiAcAc for 72 h, and relative cell viability determined
by MTT assay is plotted in the bar charts. (F) Capan1 and S2-013 cells treated with 10- and 20-mM concentrations of sodium-3-hydroxybutyrate
and lithium acetoacetate for 48 h and the relative caspase 3/7 activity are plotted. Values represented are mean ± SEM. *P<0.05; **P<0.01.
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